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Background: The suppression of selenoprotein P 
production may be a novel therapeutic target for 
reducing insulin resistance. 
Results: Selenoprotein P expression was 
suppressed by metformin treatment, but co-
administration of AMPK inhibitor or FoxO3a 
siRNA cancelled this suppression. 
Conclusion: Metformin suppresses selenoprotein 
P expression via AMPK/FoxO3a pathway. 
Significance: AMPK/FoxO3a pathway in the liver 
may be a therapeutic target for type 2 diabetes. 
 
SUMMARY 
Selenoprotein P (SeP; encoded by SEPP1 in 
humans) is a liver-derived secretory protein 
that induces insulin resistance in type 2 diabetes. 
Suppression of SeP might provide a novel 
therapeutic approach to treating type 2 diabetes, 
but few drugs that inhibit SEPP1 expression in 
hepatocytes have been identified to date. The 
present findings demonstrate that metformin 
suppresses SEPP1 expression by activating 
AMPK and subsequently inactivating FoxO3a 
in H4IIEC3 hepatocytes. Treatment with 
metformin reduced SEPP1 promoter activity in 
a concentration- and time-dependent manner; 
this effect was cancelled by co-administration of 
an AMPK inhibitor. Metformin also suppressed 
Sepp1 gene expression in the liver of mice. 
Computational analysis of transcription factor 
binding sites conserved among the species 
resulted in identification of the FoxO-binding 
site in the metformin-response element of the 
SEPP1 promoter. A luciferase reporter assay 
showed that metformin suppresses Forkhead-
response element activity and a ChIP assay 
revealed that metformin decreases binding of 
FoxO3a, a direct target of AMPK, to the SEPP1 
promoter. Transfection with siRNAs for 
Foxo3a, but not for Foxo1, canceled metformin-
induced luciferase activity suppression of 
metformin-response element of the SEPP1 
promoter. The overexpression of FoxO3a 
stimulated SEPP1 promoter activity and 
rescued the suppressive effect of metformin. 
Metformin did not affect FoxO3a expression, 
but it increased its phosphorylation and 
decreased its nuclear localization. These data 
provide a novel mechanism of action for 
metformin involving improvement of systemic 
insulin sensitivity through the regulation of SeP 
production and suggest an additional approach 
to the development of anti-diabetic drugs. 
INTRODUCTION 
Selenoprotein P (SeP; encoded by SEPP1 in 
humans) is a secretory protein produced mainly by 
the liver (1, 2). SeP contains 10 selenocysteine 
residues and is known to transport the essential 
trace element selenium from the liver to the rest of 
the body (3, 4). Our laboratory reported recently 
that SeP functions as a hepatokine that contributes 
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to insulin resistance in type 2 diabetes (5). Using 
comprehensive gene expression analyses in 
humans, hepatic gene expression levels of SEPP1 
were found to be positively correlated with the 
severity of insulin resistance in patients with type 
2 diabetes. Moreover, treatment with purified SeP 
protein impairs insulin signal transduction in both 
cell culture and animal models. Importantly, the 
RNA interference-mediated knockdown of SeP 
improves insulin resistance and hyperglycemia in 
a mouse model of type 2 diabetes, suggesting that 
the suppression of SeP production in the liver may 
be a novel therapeutic target for reducing insulin 
resistance in type 2 diabetes (5). However, few 
drugs that inhibit the production of SeP by 
hepatocytes have been identified to date. 
Metformin is widely used as an anti-diabetic 
drug globally. The primary target of metformin 
action is the liver, which abundantly expresses 
organic cation transporter (Oct)-1, a transporter for 
metformin (6, 7). Adenosine monophosphate-
activated protein kinase (AMPK) mediates 
primarily the glucose-lowering actions of 
metformin, including the suppression of hepatic 
gluconeogenesis (8). In contrast, several reports 
indicate that the oral administration of metformin 
in humans increases insulin sensitivity in skeletal 
muscle, increases serum adiponectin, and 
improves aortic arteriosclerosis (9–11). These 
reports suggest that orally administered metformin 
also exerts beneficial actions on tissues other than 
the liver, in which expression levels of Octs are 
lower. To date, however, the molecular 
mechanisms underlying the systemic actions of 
metformin are not fully understood.  
Forkhead box protein O3a (FoxO3a), which 
belongs to Forkhead transcription factors of the 
FoxO subfamily (FoxOs), is reported to be 
involved in cell cycle arrest (12), apoptosis (13), 
and the oxidative stress response (14, 15). Recently, 
Greer et al. showed that FoxO3a, but not FoxO1, 
is directly phosphorylated and activated by AMPK 
in vitro (16). FoxO3a is reported to positively 
regulate mitochondria-related genes, such as 
uncoupling proteins (UCPs), in mouse embryonic 
fibroblasts, suggesting that the direct regulation of 
FoxO3a by AMPK plays a crucial role in the 
control of the cellular energy balance. The 
phosphorylation of FoxO3a by AMPK was also 
identified in C2C12 myotubes (17), aortic vascular 
endothelial cells (18), and A549 lung cancer cells 
(19). However, the role of the AMPK/FoxO3a 
pathway in hepatocytes, an important target of 
metformin, remains unknown. 
We demonstrate here that metformin suppresses 
SEPP1 gene expression by activating AMPK and 
subsequently inactivating FoxO3a in H4IIEC3 
hepatocytes. These results suggest a novel 
mechanism underlying the glucose-lowering 
action of metformin. 
EXPERIMENTAL PROCEDURES 
Materials- The antibodies against AMPKα, 
phospho-AMPKα, FoxO1, FoxO3a, acetylated-
Lys, and Lamin A/C were purchased from Cell 
Signaling Technology (Beverly, MA). Antibody 
against phospho-Ser/Thr/Tyr was purchased from 
AnaSpec (San Jose, CA). Antibody against 
GAPDH was purchased from Santa Cruz 






pyrimidine (Compound C) were purchased from 
Sigma-Aldrich (St. Louis, MO). FoxO3a 
expression vector was provided from Ajinomoto 
Pharma (Tokyo, Japan) described before (20). 
Selenious acid was purchased from WaKo Pure 
Chemical Industries, Ltd. (Osaka, Japan). 
Metformin was provided by Dainippon Sumitomo 
Pharma (Osaka, Japan), but this company had no 
role in the study design and has no financial 
interest in the results.  
Generation of Plasmid Constructs- The human 
SEPP1 promoter region has been described 
previously (21). Fragments of approximately 1800 
bp from the human SEPP1 promoter region and the 
deletion promoter region were amplified by PCR 
using normal human genomic DNA as a template 
and the primer pairs shown in Table 1. The PCR 
product was subcloned into the luciferase reporter 
gene plasmid pGL3-basic (Promega; Madison, 
WI) and termed “SEPP1-Promoter-Luc”, “Mut-A”, 
“Mut-B”, “Mut-C”, “Mut-D”, “Mut-E”, “Mut-
DΔ1”, “Mut-DΔ2”, and “Mut-DΔ3”. Putative 
FoxO binding site deficient vector were generate 
using QuickChange Lightning Site-Directed 
Mutagenesis Kits (Agilent Technologies; Santa 
Clara CA), according to the manufacturer’s 
instructions. All inserts were conﬁrmed by DNA 
sequencing.  
Cell Culture- Studies were performed using the rat 
hepatoma cell line H4IIEC3 (American Type 
Culture Collection; Manassas, VA). Cells were 
cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies Corporation, Carlsbad, 
CA) and supplemented with 10% fetal bovine 
serum (Life Technologies), 2 mmol/l L-Glutamin 
(WaKo Pure Chemical Industries, Ltd.; Osaka, 
Japan), 100 units/ml penicillin, and 0.1 mg/ml 
streptomycin (WaKo). The cells were cultured at 
37°C in a humidified atmosphere containing 5% 
CO2.  
Measurement of GPx activity- To measure cellular 
glutathione peroxidase (cGPx) activity, a coupled 
enzyme assay, which was performed by following 
the oxidation of NADPH, was used as described 
previously (22). In brief, cells were cultured with 
DMEM/10%FBS or DMEM/10%FBS +100 nM 
selenious acid or DMEM/10%FBS +1000 nM 
selenious acid at 72 h. Then cells were fractured 
with homogenate buffer containg 0.25 M Sucrose, 
50 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 0.1 mM 
2-Mercaptoethanol. The assay conditions were as 
follows: for the cGPx assay, 0.1 M phosphate 
buffer, pH 7.4, 0.2 mM NADPH, 0.5 mM EDTA, 
1 mM NaN3, 2 mM GSH, 1 unit/ml of GSH 
reductase, and 30 µM hydrogen peroxide. The 
oxidation of NADPH was followed at 340 nm at 
37 °C, and unit of the enzyme activity was 
expressed as µmol of NADPH oxidized per minute. 
Transfection and Luciferase Reporter Gene assay- 
H4IIEC3 cells were grown in 24-well plates and 
transfected with 0.4 μg of plasmid DNA per well 
together with 1.2-μL FuGENE6 (Promega). For 
the luciferase reporter gene assays, 0.4 μg of ﬁreﬂy 
luciferase promoter construct was co-transfected 
with 0.01-μg renilla luciferase control plasmid 
(pRL-SV40; Promega), and/or 0.05-0.4 μg of 
plasmids expressing FoxO3a, or empty control 
plasmids resulting in a total DNA amount of 0.41-
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0.81 μg per well. 24 hours later, cells were treated 
with the indicated reagents, such as metformin, in 
DMEM/10% FBS for the indicated times. After 48 
hours, luciferase activities were measured using 
the Dual Luciferase assay system (Promega), as 
described previously (20).  
siRNA transfection in H4IIEC3 hepatocytes- 
H4IIEC3 hepatocytes were grown in 24-well plates 
and transiently transfected with 10 nM small 
interfering RNA (siRNA) duplex oligonucleotides 
using 1-μL Lipofectamine™ RNAiMAX (Life 
Technologies) by the reverse-transfection method 
according to the manufacturer’s instructions. 
Foxo1 and Foxo3a-specific siRNAs with the 
following sequences were synthesized (Thermo 
Scientific): Foxo1 #A: 5’-
GACAGCAAAUCAAGUUAUG-3’ (sense), 
Foxo1 #B: 5’-UUUGAUAACUGGAGUACAU-3’ 
(sense), Foxo3a #A: 5’-
GAACGUUGUUGGUUUGAAC-3’ (sense) and 
Foxo3a #B: 5’-CGUCAUGGGUCACGACAAG-
3’ (sense). Negative control siRNA was also 
utilized (Thermo Scientific). 24 hours after 
transfection, the cells were treated with metformin 
for 24 hours followed by the extraction of total 
RNA.  
Adenovirus-mediated gene transfer in H4IIEC3 
hepatocytes- Cells were transfected with 
adenoviruses as described previously (5). Briefly, 
H4IIEC3 hepatocytes were grown to 90% 
confluence in 24-well multi-plates and transfected 
with adenoviruses encoding dominant negative 
(DN) α1 and α2 AMPK, constitutive active (CA) 
AMPK, or LacZ for 4 hours. The cells were 
incubated with DMEM for 24 hours after removing 
the adenoviruses; total RNA was then extracted.  
Quantitative RT-PCR- Total RNA was extracted 
from cultured H4IIEC3 hepatocytes using a 
Genelute Mammalian Total RNA Miniprep Kit 
(Sigma). The reverse-transcription of 100 ng of 
total RNA was performed using a High-capacity 
cDNA Reverse Transcription Kit (Life 
Technologies), according to the manufacturer’s 
instructions. Quantitative RT-PCR (qRT-PCR) 
was performed using TaqMan probes (ACTB: 
4352340E; Foxo1: Rn01494868_m1; Foxo3: 
Rn01441087_m1; G6pc: Rn00565347_m1; Pck1: 
Rn01529014_m1; and Sepp1: Rn00569905_m1) 
and the 7900HT Fast Real-Time PCR System (Life 
Technologies), as described previously (23).  
Western blotting- Treated cells were collected and 
lysed as described previously (20). Protein samples 
(10 μg per lane) were subjected to SDS-PAGE and 
transferred to PVDF membranes using the iBlot 
Gel Transfer system (Life Technologies). The 
membranes were blocked, incubated with primary 
antibody, washed, and incubated with the 
secondary HRP-labeled antibody. Bands were 
visualized with the ECL Prime Western Blotting 
Detection System (GE Healthcare UK Ltd; 
Amersham Place, Little Chalfont, UK) and LAS-
3000 (Fujifilm; Tokyo, Japan). A densitometric 
analysis of blotted membranes was performed 
using ImageJ software. 
Immunoprecipitation- Immunoprecipitation of 
serine/threonine/tyrosine phosphorylated proteins 
or lysine acetylated proteins were carried out using 
Dynabeads Protein G Immunoprecipitation Kit 
(Life Technologies), according to the 
manufacturer’s instructions. The nuclear and 
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cytoplasmic fractions were extracted using a NE-
PER Nuclear and Cytoplasmic Extraction Reagent 
Kit (Pierce; Rockford, IL).  
Detection of the conserved transcription factor 
biding sites using multiple genome alignments- 
The Ensembl 12-way Enredo-Pecan-Ortheus 
(EPO) eutherian multiple alignments (12-way EPO 
alignments) (24, 25) were downloaded from 
ftp.ensembl.org/pub/release-65/emf/ensembl-
compara/epo_12_eutherian/. The 12-way EPO was 
excised to obtain the alignment block 
corresponding to the human genome coordinates 
from 10-kb upstream of the coding sequence of 
SEPP1, including the start codon. To predict the 
conserved transcription factor biding sites (TFBSs), 
the 10-kb upstream genome sequence for each of 
the 12 species was searched using TRANSFAC 
(26) MATCH™ program (27) (version 6.1) with 
varied thresholds. Then, the predicted TFBSs were 
mapped on the alignments and the conserved 
TFBSs for SEPP1 were identified. 
Chromatin immunoprecipitation assay- A 
chromatin immunoprecipitation (ChIP) assay was 
carried out using the ChIP IT Express Enzymatic 
Kit (Active Motif; Carlsbad, CA), according to the 
manufacturer’s instructions. In brief, HepG2 cells 
were treated with metformin 6 hours before being 
fixed and homogenized. Following centrifugation, 
the supernatant was used for chromatin samples. 
Chromatin samples were incubated with protein G-
coated magnetic beads and ChIP grade FoxO1 or 
FoxO3a antibodies (abcam; Cambridge, MA) 
overnight at 4°C. Following washing and elution, 
a reaction solution was used as the template for 
PCR. PCR primers were set for amplification of 
the Mut-DΔ2 region of the SEPP1 promoter, as 
follows: Forward: 5’- 
GCACTTGCTACTTTCTTTTAAGTTG -3’; and 
Reverse: 5’- 
CACAGCAGCACACTCTGATATTTAT -3’.  
Animals- 12 weeks old C57BL/6J female mice 
were obtained from CLEA Japan, Inc. (Tokyo, 
Japan). All animals were housed in a 12 hours 
light/dark cycle and allowed free access to food 
and water. Following the fasting for 4 hours, mice 
were administrated 300 mg/kg of metformin. 4 
hours later, mice were anesthetized and sacrificed 
to allow isolation of liver tissue.  
Statistical Analysis- Results are expressed as 
means ± standard deviation (SD). Significance was 
tested by one-way analysis of variance (ANOVA) 
with the Bonferroni method and differences were 
considered statistically significant at a P value of 
less than 0.05. 
RESULTS 
Metformin suppresses SEPP1 expression at the 
promoter level- The effects of metformin on Sepp1 
expression in H4IIEC3 hepatocytes were 
examined. Metformin suppressed Sepp1 mRNA 
expression in a concentration- and time-dependent 
manner, similarly to G6pc and Pck1 that encode 
representative gluconeogenic enzymes glucose-6-
phosphatase and phosphoenolpyruvate 
carboxykinase 1, respectively (Fig. 1A and 1B). 
These results are consistent with a previous report 
using rat primary hepatocytes (28). Next, the 
effects of metformin on SEPP1 promoter activity 
were examined. The human SEPP1 promoter 
region was cloned to a luciferase reporter vector as 
reported previously (21). The present sequence 
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completely corresponded to the reference sequence 
of the the National Center for Biotechnology 
Information (NCBI), but it missed one thymidine 
against the sequence of previous report (accession 
number Y12262) (Supplement Fig. S1). Similar to 
the mRNA results, metformin suppressed SEPP1 
promoter activity in a concentration- and time-
dependent manner (Fig. 1C & 1D), suggesting that 
it directly decreases SEPP1 transcriptional activity 
in H4IIEC3 hepatocytes.  
To confirm whether the present experimental 
condition (DMEM/10%FBS) supplied selenium 
sufficiently enough to synthesize selenoproteins 
for cultured cells, cGPx activity was measured 
with or without additional selenium supplement. 
Supplement Fig. S2 indicated that supplementation 
of 100 nM or 1000 nM selenious acid to 
DMEM/10%FBS increased cGPx activity more 
than 3 times, suggesting that our experimental 
condition was insufficient to maximize 
selenoprotein synthesis. However, the current 
activity of cGPx in the cells cultured at 
DMEM/10%FBS (233 U/g) corresponded to the 
levels previously reported in the normal rat liver 
tissue (120 - 1800 U/g) (29, 30). Because these 
results suggest that the culture condition of 
DMEM/10%FBS was physiological, we used this 
condition in the following cellular experiments. 
The action of metformin on Sepp1 was also 
examined in mice. Following the fasting for 4 
hours, 12 weeks old female C57BL/6J mice were 
administrated 300 mg/kg of metformin. Metformin 
decreased blood glucose levels by 30% (Fig. 1E) 
and tended to down-regulate gene expression for 
G6pc and Pck1 after 4 hours. Gene expression of 
Sepp1 was significantly decreased by metformin 
(Fig. 1F). These results indicate that metformin 
suppresses gene expression for Sepp1 in the liver 
of mice, as well as in the cultured hepatocytes. 
Metformin suppresses SEPP1 promoter activity 
via AMPK activation- Metformin is known to exert 
anti-diabetic effects by activating AMPK 
pathways (31). Hence, to determine whether 
AMPK pathways are involved in the metformin-
induced suppression of SEPP1 promoter activity, 
cells were treated with compound C, a 
representative AMPK inhibitor. Findings 
confirmed that the metformin-induced 
phosphorylation of AMPK and acetyl-CoA 
carboxylase (ACC) was canceled by the co-
administration of compound C in H4IIEC3 
hepatocytes (Fig. 2A). Co-administration of 
compound C partly rescued the cells from the 
inhibitory effects of metformin on the SEPP1 
promoter (Fig. 2B), and increased SEPP1 promoter 
activity in the absence of metformin (Fig. 2B). In 
contrast, treatment with AICAR, a known activator 
of AMPK, decreased SEPP1 promoter activity 
similarly to metformin (Fig. 2C). To determine 
whether AMPK pathways were involved in SEPP1 
promoter activity, H4IIEC3 hepatocytes were 
infected with an adenovirus encoding CA- or DN-
AMPK. Transfection with CA-AMPK suppressed 
Sepp1 and G6pc mRNA expression (Fig. 2D) 
while transfection with DN-AMPK enhanced 
Sepp1 and G6pc mRNA expression (Fig. 2E). 
These results suggest that metformin decreases 
SEPP1 promoter activity, at least partly, by 
activating AMPK. 
Metformin-response element in the SEPP1 
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promoter includes the FoxO binding site- To 
determine the nature of the metformin-response 
element in the SEPP1 promoter region, several 
deletion mutants of the SEPP1 promoter were 
constructed (Fig. 3A). Promoter activity of Mut-A 
to Mut-D, but not Mut-E, was suppressed by 
metformin treatment (Fig. 3A) indicating that the 
metformin-response element of the SEPP1 
promoter exists in Mut-D. Additional deletion 
mutants of Mut-D were constructed and named 
Mut-DΔ1 to DΔ3. Mut-DΔ1 and DΔ2, but not 
Mut-DΔ3, were suppressed by metformin (Fig. 
3B), indicating that the metformin-response 
element in the SEPP1 promoter is localized in the 
Mut-DΔ2 sequence.  Using computational 
analysis to identify conserved TFBSs among the 
species (see EXPERIMENTAL PROCEDURES), 
several putative TFBSs were identified in the Mut-
DΔ2 sequence (Supplement Fig. S3).  Because 
early reports indicate that AMPK directly 
phosphorylates FoxO3a and regulates its 
transcriptional activity (16), this investigation 
focused on the two putative FoxO binding sites 
(Fig. 4A).  
Metformin suppresses FoxO activity via AMPK 
activation- To determine whether metformin 
treatment influences FoxO activity, a forkhead-
response element (FHRE)-Luc vector that includes 
three tandems of FHREs ligated with a luciferase 
gene was utilized (32). This vector was used as a 
reporter of FoxO-responsive promoter activity (33). 
Metformin treatment suppressed FHRE activity, 
and concurrent treatment with compound C 
completely cancelled this suppression (Fig. 4B). In 
addition, treatment with compound C stimulated 
FHRE activity in the absence of metformin (Fig. 
4B), while AICAR treatment suppressed FHRE 
activity (Fig. 4C). These results suggest that 
metformin suppresses FHRE activity via AMPK 
activation. To determine the critical FoxO binding 
site for metformin-induced SEPP1 suppression, 
we constructed luciferase vectors which deleted 
either of two putative FoxO binding sites and 
named Mut-DΔ2-ΔFoxO #A or #B, respectively 
(Supplement Fig. S4). Luciferase assay using these 
vectors revealed that putative FoxO binding site 
#B was essential for metformin-induced SEPP1 
suppression (Fig. 4D). Because the assays using 
these vectors are not specific to FoxO3a activity, 
the interaction of FoxO proteins with DNA 
sequences in the SEPP1 promoter was examined 
using a ChIP assay. For the ChIP assay, HepG2 
cells were utilized to evaluate the human SEPP1 
promoter. Metformin suppressed SEPP1 
expression in HepG2 cells as well as H4IIEC3 cells 
(data not shown). The ChIP assay indicates that 
treatment with metformin decreased the binding of 
FoxO3a to SEPP1 promoter, whereas it increased 
the binding of FoxO1 (Fig. 4E). These results 
suggest that FoxO3a, but not FoxO1, is associated 
with the metformin-induced suppression of SEPP1 
expression.  
Metformin suppresses SEPP1 expression via 
FoxO3a inactivation- Next, we examined whether 
the specific knockdown of endogenous Foxo3a or 
Foxo1 affects Sepp1 expression in H4IIEC3 
hepatocytes. Transfection with Foxo3a- or Foxo1-
specific siRNA resulted in a ~50% reduction in 
mRNA levels of Foxo3a or Foxo1 (Fig. 5A). 
Knockdown of both Foxo1 and Foxo3a resulted in 
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a significant down-regulation of Sepp1 expression 
(Fig. 5A). Interestingly, mRNA levels of G6pc 
were decreased by Foxo3a knockdown (Fig. 5A), 
suggesting that not only FoxO1 but also FoxO3a 
positively regulates the expression of the 
gluconeogenesis-related genes in H4IIEC3 
hepatocytes. Next, we assessed whether 
knockdown of Foxo3a selectively affects the 
inhibitory action of metformin on SEPP1 promoter. 
Transfection with siRNAs for Foxo3a, but not for 
Foxo1, canceled metformin-induced suppression 
of Mut-DΔ2 luciferase activity (Fig. 5B). These 
results suggest that the metformin-induced 
suppression of Sepp1 is dependent on FoxO3a, but 
not on FoxO1. 
Whether FoxO3a overexpression influences the 
action of metformin on SEPP1 promoter activity 
was also investigated. The FoxO3a protein was 
overexpressed in a concentration-dependent 
manner in cells transfected with the pCMV6-
FoxO3a expression vector (Fig. 5C). 
Overexpression of FoxO3a significantly enhanced 
SEPP1 promoter activity (Fig. 5D), and 
transfection with pCMV6-FoxO3a rescued the 
cells from the suppressive effect of metformin on 
SEPP1 promoter activity in a concentration-
dependent manner (Fig. 5D and 5E). These results 
indicate that metformin decreases SEPP1 promoter 
activity and gene expression via FoxO3a 
inactivation in H4IIEC3 hepatocytes. 
Metformin decreases FoxO3a protein in the 
nuclear components- To elucidate the mechanism 
by which metformin inactivates FoxO3a, 
phosphorylation and acetylation of FoxO3a were 
examined in hepatocytes treated with metformin. 
Metformin treatment neither altered mRNA levels 
of Foxo3a (Fig 6A) nor protein levels of FoxO3a 
(Fig. 6B). However, immunoprecipitation 
experiments revealed that treatment with 
metformin phosphorylated FoxO3a, but not FoxO1 
in H4IIEC hepatocytes (Fig. 6B and 6C, 
Supplementary Fig. S5). Because a previous report 
indicated that FoxO3a, as well as FoxO1, is 
deacetylated by sirtuin family proteins 
downstream of AMPK (34), we examined the 
deacetylation of FoxO3a and FoxO1. Acetylation 
of both FoxO1 and FoxO3a was unaffected by 
metformin administration (Fig. 6B and 6C, 
Supplementary Fig. S5). To determine the 
intracellular localization of FoxO3a, the cytosolic 
and nuclear components of the FoxO3a protein 
were fractioned. FoxO3a and FoxO1 protein levels 
were decreased by metformin treatment in the 
nuclear fraction (Fig. 6D). These results suggest 
that metformin inactivates FoxO3a by decreasing 
FoxO3a protein levels in the nucleus and 
subsequently inhibiting the binding of FoxO3a to 
the SEPP1 promoter.  
 
DISCUSSION 
Our data demonstrate that metformin suppresses 
production of the insulin resistance-inducing 
hepatokine SeP by activating AMPK and 
subsequently inactivating FoxO3a in H4IIEC3 
hepatocytes. During the course of this study, it was 
reported that metformin decreases mRNA levels of 
Sepp1 in rat primary hepatocytes (28), however, 
the molecular mechanisms by which metformin 
reduces the expression of Sepp1 were not fully 
understood. Our data demonstrate that the 
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AMPK/FoxO3a pathway downstream of 
metformin action plays a major role in the 
regulation of SEPP1 expression in cultured 
hepatocytes. Our data suggest a previously 
unrecognized mechanism of action of metformin in 
combating the systemic insulin resistance in type 2 
diabetes.  
The finding that FoxO3a positively regulates 
Sepp1 and G6pc expression in H4IIEC3 
hepatocytes supports the suggestion that FoxO3a 
plays an important role in glucose homeostasis. 
The ability of FoxO1 to increase the expression of 
gluconeogenetic genes has been confirmed (35). 
To date, however, little information concerning the 
involvement of FoxO3a in glucose metabolism is 
available. Certainly, no defects in glucose 
metabolism have been described in FoxO3a 
deficient mice (36) suggesting that the function of 
FoxO3a in glucose metabolism is compensated for 
by FoxO1. Indeed, Haeusler et al. (37) reported 
that triple liver-specific ablation of FoxO1, 
FoxO3a, and FoxO4 causes a more pronounced 
hypoglycemia and increased insulin sensitivity in 
mice compared to a single knockout of FoxO1. The 
present findings indicate that FoxO proteins, 
including FoxO3a, regulate hepatic glucose 
metabolism in a coordinated manner. These data 
reveal that FoxO3a, the downstream target of 
metformin/AMPK, positively regulates SEPP1 
transcriptional activity in cultured hepatocytes 
independently of FoxO1 and suggest that FoxO3a 
participates in glucose homeostasis via regulation 
of the hepatic production of SeP, an insulin 
resistance-inducing hepatokine.  
Knock down of Foxo3a, but not Foxo1, rescued 
the cells from metformin-induced inactivation of 
SEPP1 promoter although knockdown of both 
Foxo3a and Foxo1 down-regulated Sepp1 in the 
absence of metformin (Fig. 5A and 5B). These 
results are in harmony with early reports showing 
that FoxO1 positively regulates Sepp1 expression 
in cultured hepatocytes (38, 39). The current data 
suggest that both FoxO3a and FoxO1 positively 
regulate expression of SEPP1 in the basal 
conditions, but FoxO3a has a dominant role in the 
suppression of SEPP1 downstream of 
metformin/AMPK pathway in H4IIEC3 
hepatocytes. Interestingly, metformin selectively 
phosphorylated and deacetylated FoxO3a, but not 
FoxO1 (Fig. 6B and 6C). This FoxO3a-selective 
phosphorylation by metformin is consistent with 
the previous report showing that AMPK-induced 
phosphorylation displays a strong preference 
toward FoxO3 compared with FoxO1 by using in 
vitro kinase assays (16).  
The current study is the first to demonstrate the 
decreased nuclear localization and subsequent 
transcriptional inactivation of FoxO3a by AMPK 
downstream of metformin in the cultured 
hepatocytes. Greer et al. (16) identified FoxO3a as 
a direct phosphorylation target of AMPK using in 
vitro kinase assays. However, the authors reported 
that phosphorylation by AMPK increases FoxO3a 
transcriptional activity without affecting FOXO3A 
subcellular localization in mouse embryonic 
fibroblasts or 293T cells. A similar activation of 
FoxO3a by AMPK was reported in C2C12 
myotubes (17). In this respect, our results suggest 
that the AMPK-induced inactivation of FoxO3a is 
hepatocyte-specific. When FoxO proteins are 
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phosphorylated by Akt, the dissociation of nuclear 
co-factors from FoxO is thought to be required for 
nuclear exclusion of FoxO (40). Hence, the 
difference in nuclear co-activator/co-repressor 
recruitment between hepatocytes and other cells 
might explain differences in the action of AMPK 
on FoxO3a cellular localization and transcriptional 
activity. Notably, the siRNA-induced knockdown 
of Foxo3a decreased Sepp1 and G6pc mRNA 
levels in H4IIEC3 hepatocytes, suggesting that the 
AMPK/FoxO3a pathway in the liver regulates 
gluconeogenesis and the production of the 
hepatokine SeP. These findings shed light on a 
previously unrecognized role for the 
AMPK/FoxO3a pathway in the regulation of 
glucose metabolism in the liver. 
The cancellation of the metformin-induced 
suppression of SeP by compound C, a known 
inhibitor of the AMPK pathway, was only partial 
(Fig. 2B). Likewise, the overexpression of FoxO3a 
only partially canceled the suppressive action of 
metformin on Sepp1 gene expression (Fig. 6D & 
6E). These results suggest that metformin 
decreases Sepp1 gene expression through both 
AMPK/FoxO3a-dependent and other independent 
pathways. Recently, Kalender et al. (41) reported 
that metformin acts to suppress mTORC1 
signaling in an AMPK-independent manner. In 
addition, Guigas et al. (42) found that metformin 
inhibits glucose phosphorylation in primary 
cultured hepatocytes independently of AMPK 
activity. Additional studies are needed to elucidate 
the AMPK-independent actions of metformin on 
Sepp1 expression in H4IIEC3 hepatocytes.  
The present sequence of SEPP1 promoter 
completely corresponds to the refseq of the NCBI, 
but it misses one thymidine against the sequence of 
a previous report (21). This site had been reported 
as SNP site (reference SNP ID: rs201851607). 
Because both allele origin and minor allele 
frequency of this SNP site are not available, it is 
difficult to prove which genome sequence is 
“correct”. At least, this SNP site does not seem to 
affect basal SEPP1 promoter activity. In addition, 
metformin responsible element identified in the 
current paper locates in the other region of the SNP 
site. Thus, we consider that the effect of this SNP 
on the conclusion of this paper is negligible. 
A limitation of the present study is that the 
effects of metformin on SeP expression were not 
investigated in human samples. The metformin 
concentrations used in this study (0.25-1 mM) 
were higher than the blood levels of metformin in 
patients treated with conventional doses of the 
drug (10 to 40 μM). However, it has been pointed 
out that concentrations of metformin in liver tissue 
are much higher than those in the blood because 
the liver receives portal vein blood which may 
contain materially higher doses of metformin than 
plasma (43). An early report indicated that 
metformin concentrations in the liver were greater 
than 250 μmol/kg in a STZ diabetic mouse model 
treated with 50 mg/kg metformin (44). One 
previous study used 0.25-1 mM metformin in rat 
primary hepatocytes as more physiological range 
of intrahepatic concentration (43). In addition, we 
show that administration of 300 mg/kg of 
metformin was effective on hepatic expression for 
Sepp1 in C57BL/6J mice (Fig. 1F). Although 
clinical trials are necessary, we speculate here that 
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treatment with metformin decreases blood levels of 
SeP in patients with diabetes. Additionally, the 
contribution of SeP suppression to the anti-diabetic 
actions of metformin should be confirmed by 
additional investigations using Sepp1-knockout 
mice. 
In summary, the present data provide a novel 
mechanism of action for metformin involving 
improvement of systemic insulin sensitivity via the 
regulation of SeP production (Fig. 6E), and suggest 
that AMPK/FoxO3a pathway in the liver may be a 







1.  Burk, R. F., and Hill, K. E. (2005) Selenoprotein P: an extracellular protein with unique physical 
characteristics and a role in selenium homeostasis. Annu. Rev. Nutr. 25, 215–35 
2.  Carlson, B. A., Novoselov, S. V, Kumaraswamy, E., Lee, B. J., Anver, M. R., Gladyshev, V. N., and 
Hatfield, D. L. (2004) Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse 
liver demonstrates an essential role of selenoproteins in liver function. J. Biol. Chem. 279, 8011–7 
3.  Schomburg, L., Schweizer, U., Holtmann, B., Flohé, L., Sendtner, M., and Köhrle, J. (2003) Gene 
disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem. J. 370, 
397–402 
4.  Hill, K. E., Zhou, J., McMahan, W. J., Motley, A. K., Atkins, J. F., Gesteland, R. F., and Burk, R. F. 
(2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. J. Biol. Chem. 278, 
13640–6 
5.  Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., 
Ando, H., Takeshita, Y., Ota, T., Sakurai, M., Yamashita, T., Mizukoshi, E., Yamashita, T., Honda, 
M., Miyamoto, K., Kubota, T., Kubota, N., Kadowaki, T., Kim, H.-J., Lee, I., Minokoshi, Y., Saito, 
Y., Takahashi, K., Yamada, Y., Takakura, N., and Kaneko, S. (2010) A liver-derived secretory 
protein, selenoprotein P, causes insulin resistance. Cell Metab. 12, 483–95 
6.  Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., and Sugiyama, Y. (2002) 
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. 
Pharmacol. Exp. Ther. 302, 510–5 
7.  Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, 
L., Lo, J. C., Burchard, E. G., Brett, C. M., and Giacomini, K. M. (2007) Effect of genetic variation in 
the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422–31 
8.  Boyle, J. G., Salt, I. P., and McKay, G. A. (2010) Metformin action on AMP-activated protein kinase: 




9.  Malin, S. K., Gerber, R., Chipkin, S. R., and Braun, B. (2012) Independent and combined effects of 
exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 
35, 131–6 
10.  Singh, S., Akhtar, N., and Ahmad, J. (2012) Plasma adiponectin levels in women with polycystic 
ovary syndrome: impact of Metformin treatment in a case-control study. Diabetes Metab. Syndr. 6, 
207–11 
11.  Shargorodsky, M., Omelchenko, E., Matas, Z., Boaz, M., and Gavish, D. (2012) Relation between 
augmentation index and adiponectin during one-year metformin treatment for nonalcoholic 
steatohepatosis: effects beyond glucose lowering? Cardiovasc. Diabetol. 11, 61 
12.  Medema, R. H., Kops, G. J., Bos, J. L., and Burgering, B. M. (2000) AFX-like Forkhead transcription 
factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–7 
13.  Luo, X., Puig, O., Hyun, J., Bohmann, D., and Jasper, H. (2007) Foxo and Fos regulate the decision 
between cell death and survival in response to UV irradiation. EMBO J. 26, 380–90 
14.  Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, 
T.-T., Bos, J. L., Medema, R. H., and Burgering, B. M. T. (2002) Forkhead transcription factor 
FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316–21 
15.  Olmos, Y., Valle, I., Borniquel, S., Tierrez, A., Soria, E., Lamas, S., and Monsalve, M. (2009) Mutual 
dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J. Biol. Chem. 284, 
14476–84 
16.  Greer, E. L., Oskoui, P. R., Banko, M. R., Maniar, J. M., Gygi, M. P., Gygi, S. P., and Brunet, A. 
(2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 
transcription factor. J. Biol. Chem. 282, 30107–19 
17.  Sanchez, A. M. J., Csibi, A., Raibon, A., Cornille, K., Gay, S., Bernardi, H., and Candau, R. (2012) 
AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction 
with Ulk1. J. Cell. Biochem. 113, 695–710 
18.  Li, X.-N., Song, J., Zhang, L., LeMaire, S. A., Hou, X., Zhang, C., Coselli, J. S., Chen, L., Wang, X. 
L., Zhang, Y., and Shen, Y. H. (2009) Activation of the AMPK-FOXO3 pathway reduces fatty acid-




19.  Lützner, N., Kalbacher, H., Krones-Herzig, A., and Rösl, F. (2012) FOXO3 is a glucocorticoid 
receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a 
positive autoregulatory loop. PLoS One 7, e42166 
20.  Honda, M., Takehana, K., Sakai, A., Tagata, Y., Shirasaki, T., Nishitani, S., Muramatsu, T., 
Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shimakami, 
T., Yi, M., Lemon, S. M., Suzuki, T., Wakita, T., and Kaneko, S. (2011) Malnutrition impairs 
interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. 
Gastroenterology 141, 128–40, 140.e1–2 
21.  Dreher, I., Jakobs, T. C., and Köhrle, J. (1997) Cloning and characterization of the human 
selenoprotein P promoter. Response of selenoprotein P expression to cytokines in liver cells. J. Biol. 
Chem. 272, 29364–71 
22.  Takebe, G., Yarimizu, J., Saito, Y., Hayashi, T., Nakamura, H., Yodoi, J., Nagasawa, S., and 
Takahashi, K. (2002) A comparative study on the hydroperoxide and thiol specificity of the 
glutathione peroxidase family and selenoprotein P. J. Biol. Chem. 277, 41254–8 
23.  Nakamura, S., Takamura, T., Matsuzawa-Nagata, N., Takayama, H., Misu, H., Noda, H., Nabemoto, 
S., Kurita, S., Ota, T., Ando, H., Miyamoto, K.-I., and Kaneko, S. (2009) Palmitate induces insulin 
resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J. 
Biol. Chem. 284, 14809–18 
24.  Flicek, P., Amode, M. R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., 
Fairley, S., Fitzgerald, S., Gil, L., Gordon, L., Hendrix, M., Hourlier, T., Johnson, N., Kähäri, A. K., 
Keefe, D., Keenan, S., Kinsella, R., Komorowska, M., Koscielny, G., Kulesha, E., Larsson, P., 
Longden, I., McLaren, W., Muffato, M., Overduin, B., Pignatelli, M., Pritchard, B., Riat, H. S., 
Ritchie, G. R. S., Ruffier, M., Schuster, M., Sobral, D., Tang, Y. A., Taylor, K., Trevanion, S., 
Vandrovcova, J., White, S., Wilson, M., Wilder, S. P., Aken, B. L., Birney, E., Cunningham, F., 
Dunham, I., Durbin, R., Fernández-Suarez, X. M., Harrow, J., Herrero, J., Hubbard, T. J. P., Parker, 
A., Proctor, G., Spudich, G., Vogel, J., Yates, A., Zadissa, A., and Searle, S. M. J. (2012) Ensembl 
2012. Nucleic Acids Res. 40, D84–90 
25.  Paten, B., Herrero, J., Beal, K., Fitzgerald, S., and Birney, E. (2008) Enredo and Pecan: genome-wide 
mammalian consistency-based multiple alignment with paralogs. Genome Res. 18, 1814–28 
26.  Wingender, E. (2008) The TRANSFAC project as an example of framework technology that supports 
the analysis of genomic regulation. Brief. Bioinform. 9, 326–32 
16 
 
27.  Kel, A. E., Gössling, E., Reuter, I., Cheremushkin, E., Kel-Margoulis, O. V, and Wingender, E. 
(2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic 
Acids Res. 31, 3576–9 
28.  Speckmann, B., Sies, H., and Steinbrenner, H. (2009) Attenuation of hepatic expression and secretion 
of selenoprotein P by metformin. Biochem. Biophys. Res. Commun. 387, 158–63 
29.  A. Łukaszewicz-Hussain, and J. Moniuszko-Jakoniuk (2004) Liver Catalase, Glutathione Peroxidase 
and Reductase Activity, Reduced Glutathione and Hydrogen Peroxide Levels in Acute Intoxication 
with Chlorfenvinphos, an Organophosphate Insecticide. Polish J. Environ. Stud. 13, 303–309 
30.  Magwere, T., Naik, Y. S., and Hasler, J. A. (1997) Effects of chloroquine treatment on antioxidant 
enzymes in rat liver and kidney. Free Radic. Biol. Med. 22, 321–7 
31.  Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., 
Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-
activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–74 
32.  Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., 
Blenis, J., and Greenberg, M. E. (1999) Akt promotes cell survival by phosphorylating and inhibiting 
a Forkhead transcription factor. Cell 96, 857–68 
33.  Eckers, A., Sauerbier, E., Anwar-Mohamed, A., Hamann, I., Esser, C., Schroeder, P., El-Kadi, A. O. 
S., and Klotz, L.-O. (2011) Detection of a functional xenobiotic response element in a widely 
employed FoxO-responsive reporter construct. Arch. Biochem. Biophys. 516, 138–45 
34.  Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., 
Puigserver, P., and Auwerx, J. (2009) AMPK regulates energy expenditure by modulating NAD+ 
metabolism and SIRT1 activity. Nature 458, 1056–60 
35.  Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., 
Altomonte, J., Dong, H., Accili, D., and Spiegelman, B. M. (2003) Insulin-regulated hepatic 
gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423, 550–5 
36.  Hosaka, T., Biggs, W. H., Tieu, D., Boyer, A. D., Varki, N. M., Cavenee, W. K., and Arden, K. C. 
(2004) Disruption of forkhead transcription factor (FOXO) family members in mice reveals their 
functional diversification. Proc. Natl. Acad. Sci. U. S. A. 101, 2975–80 
17 
 
37.  Haeusler, R. a, Kaestner, K. H., and Accili, D. (2010) FoxOs function synergistically to promote 
glucose production. J. Biol. Chem. 285, 35245–8 
38.  Speckmann, B., Walter, P. L., Alili, L., Reinehr, R., Sies, H., Klotz, L.-O., and Steinbrenner, H. 
(2008) Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha 
with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. Hepatology 48, 1998–2006 
39.  Walter, P. L., Steinbrenner, H., Barthel, A., and Klotz, L.-O. (2008) Stimulation of selenoprotein P 
promoter activity in hepatoma cells by FoxO1a transcription factor. Biochem. Biophys. Res. Commun. 
365, 316–21 
40.  Van Der Heide, L. P., Hoekman, M. F. M., and Smidt, M. P. (2004) The ins and outs of FoxO 
shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 380, 297–309 
41.  Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., 
Dennis, P., Schlager, J. J., Marette, A., Kozma, S. C., and Thomas, G. (2010) Metformin, independent 
of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390–401 
42.  Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N., Vertommen, D., Andreelli, F., 
Viollet, B., and Hue, L. (2006) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and 
metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent 
effect on glucokinase translocation. Diabetes 55, 865–74 
43.  Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., 
Andreelli, F., and Viollet, B. (2010) Metformin inhibits hepatic gluconeogenesis in mice 
independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 
120, 2355–69 
44.  Wilcock, C., and Bailey, C. J. (1994) Accumulation of metformin by tissues of the normal and 
diabetic mouse. Xenobiotica 24, 49–57  
Acknowledgments- The authors thank Dr. Atsushi Hirao (Kanazawa University) for providing a vector 
for FHRE-Luc and Ms. Maki Wakabayashi (Kanazawa University) for technical assistance. The authors 
thank Fabienne Foufelle of Universite´ Pierre et Marie Curie for providing adenovirus vector encoding 
DN-AMPK. The authors thank In-kyu Lee of Kyungpook National University for providing adenovirus 
vector encoding CA-AMPK. This work was supported by Grants-in-Aid from the Ministry of Education, 
Culture, Sports, Science and Technology, Japan (to H.M., T.T. and S.K.) and research grants from 





FIGURE 1. Metformin suppressed Sepp1 gene expression in H4IIEC3 hepatocytes and livers of C57BL/6J 
mice. A and B: Metformin suppressed Sepp1 mRNA expression in a concentration- and time-dependent manner. 
H4IIEC3 cells were treated with the indicated concentrations of metformin for the indicated times. Expression 
values were normalized to Actb mRNA. Data represent means ± SD (n = 4). *, P < 0.05; **, P < 0.01; ***, P 
< 0.001 versus vehicle-treated cells or 0 h. C and D: SEPP1 promoter activity was suppressed in a 
concentration- and time-dependent manner. H4IIEC3 cells were transfected with the SEPP1 promoter reporter 
vector and control reporter vector. 24 h later, the cells were treated with the indicated concentrations of 
metformin for the indicated times. Values were normalized to the activity of the control luciferase vector. Data 
represent means ± SD (n = 4). **, P < 0.01; ***, P < 0.001 versus vehicle-treated cells or 0 h. E and F: 
Metformin suppressed Sepp1 mRNA expression in livers of C57BL/6J mice. Following the fasting for 4 hours, 
12 weeks old female C57BL/6J mice were administrated 300 mg/kg of metformin. 4 h after metformin 
administration, mice were sacrificed and liver mRNA expression was examined. Expression values were 
normalized to Actb mRNA. Data represent means ± SD (n = 7). *, P < 0.05 versus PBS-injected mice. 
FIGURE 2. Metformin suppressed SEPP1 promoter activity via AMPK pathway in H4IIEC3 hepatocytes. A: 
Metformin-induced AMPK phosphorylation in the absence or presence of compound C. H4IIEC3 cells were 
treated with the indicated concentrations of metformin and compound C for 24 h. AMPK phosphorylation was 
examined by Western blotting. B: Compound C treatment recovered metformin-induced suppression of the 
SEPP1 promoter. H4IIEC3 cells were transfected with the SEPP1 promoter reporter vector and control reporter 
vector at 24 h and then treated with the indicated concentrations of metformin and compound C for 48 h. 
Signals were normalized to the control reporter vector. Data represent means ± SD (n = 4). ***, P < 0.001. C: 
AICAR suppressed SEPP1 promoter activity. H4IIEC3 cells were transfected with the SEPP1 promoter 
reporter vector and control reporter vector at 24 h and then treated with 0.4 mM AICAR for 24 h. Signals were 
normalized to the control reporter vector. Data represent means ± SD (n = 4). ***, P < 0.001. D and E: Influence 
of adenoviruses carrying CA- or DN-AMPK. H4IIEC3 cells were infected with adenoviruses encoding CA, 
DN or LacZ. Expression values were normalized to Actb mRNA. Data represent means ± SD (n = 4). **, P < 
0.01; ***, P < 0.001. 
FIGURE 3. SEPP1 promoter activity of deletion mutants. A and B: Structure and luciferase activity of 
promoter-deletion mutants. The sequences deleted within the constructs are shown as thin lines. The remaining 
parts of the SEPP1 promoter were fused to a luciferase reporter gene. H4IIEC3 cells were transfected with 
each reporter vector and control reporter vector at 24 h and then treated with the indicated concentrations of 
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metformin for 48 h. Signals were normalized to the control reporter vector. Data represent means ± SD (n = 4). 
***, P < 0.001 versus vehicle-treated cells. 
FIGURE 4. Activation of the AMPK suppressed FoxO activity. A: Putative FoxO3a binding sites of Mut-DΔ2 
sequence. Detection of the conserved transcription factor biding sites (TFBSs) was performed using multiple 
genome alignments and the highlighted putative transcriptional factor binding sites. B: FoxO activity in the 
absence or presence of metformin and compound C. H4IIEC3 cells were transfected with the FHRE-Luc vector 
and control reporter vector at 24 h and then treated with the indicated concentrations of metformin and 
compound C for 48 h. Signals were normalized to the control reporter vector. Data represent means ± SD (n = 
4). **, P < 0.01; ***, P < 0.001. C: FoxO activity in the absence or presence of AICAR. H4IIEC3 cells were 
transfected with the FHRE-Luc vector and control reporter vector at 24 h and then treated with the indicated 
concentrations of AICAR for 24 h. Signals were normalized to the control reporter vector. Data represent 
means ± SD (n = 4). *, P < 0.05 versus vehicle-treated cells. D: Deficiency of putative FoxO bindng site 
cancelled metformin-induced suppression of SEPP1 promoter activity. H4IIEC3 cells were transfected with 
each reporter vector and control reporter vector at 24 h and then treated with the indicated concentrations of 
metformin for 24 h. Signals were normalized to the control reporter vector. Data represent means ± SD (n = 4). 
***, P < 0.001 versus vehicle-treated cells. E: Chromatin immunoprecipitation assay of HepG2 cells treated 
with metformin. HepG2 Cells were treated with metformin for 6 h. Chromatin samples precipitated with anti-
FoxO3a, anti-FoxO1, or normal IgG were amplified using primers for the -200 to -100 bp region of the human 
SEPP1 promoter. 
FIGURE 5. Metformin suppressed SeP expression via FoxO3a. A: Efficiency of Foxo3a siRNA and Foxo1 
siRNA. H4IIEC3 cells were transfected with Foxo3a siRNAs or Foxo1 siRNAs or a negative control (NC) 
siRNA at 48 h. Knockdown efficiency was assessed by real-time PCR. Expression values were normalized to 
Actb mRNA. Data represent means ± SD (n = 4). **, P < 0.01; ***, P < 0.001 versus NC siRNA-treated cells. 
B: Luciferase activity of Mut-DΔ2 treated with Foxo3a or Foxo1 siRNA and metformin. H4IIEC3 cells were 
transfected with Foxo3a siRNAs or Foxo1 siRNAs or NC siRNA at 24 h and then transfected with Mut-DΔ2 
vector and control reporter vector. 24 h after transfection, cells were treated with the indicated concentrations 
of metformin for 24 h. Signals were normalized to the control reporter vector. Data represent means ± SD (n = 
4). ***, P < 0.001 versus vehicle-treated cells. C: Protein levels in the presence of the FoxO3a overexpression 
vector. H4IIEC3 cells were transfected with the pCMV-FoxO3a vector or pCMV empty vector at 24 h. FoxO3a 
protein levels were then assessed by Western blotting. D: SEPP1 promoter activity transfected with the 
FoxO3a-overexpression vector. H4IIEC3 cells wnsfected with the FoxO3a overexpression vector, SEPP1 
promoter reporter vector, and control reporter vectoere trar at 24 h and then treated with the indicated 
concentrations of metformin for 48 h. Data represent means ± SD (n = 3-4). ***, P < 0.001 versus control, ††, 
P < 0.01; †††, P < 0.001 versus vehicle-treated cells. E: % inhibition of SEPP1 promoter activity by metformin. 
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Suppression ratios of SEPP1 promoter activity were calculated based on the data in Fig. 5E. Data represent 
means ± SD (n = 3-4). **, P < 0.01; ***, P < 0.001 versus control. 
FIGURE 6. Metformin treatment did not suppress FoxO3a expression but did suppress its activity. A: FoxO3a 
mRNA expression in H4IIEC3 hepatocytes treated with metformin for 6 h. Expression values were normalized 
to Actb mRNA. Data represent means ± SD (n = 5-6). B and C: Modification of FoxOs proteins by metformin 
treatment. Proteins were extracted after 6 h of metformin treatment. Immunoblotting were performed using 
anti-FoxO3a antibody (B) or anti-FoxO1 antibody (C). Data represent means ± SD (n = 3). **, P < 0.01. D: 
Intracellular localization of FoxO3a and FoxO1 in H4IIEC3 hepatocytes upon treatment with metformin. 
Proteins were extracted after 6 h of metformin treatment. E: Scheme of SeP suppression by metformin in the 
liver. FoxO3a positively regulates SEPP1 promoter activity. Metformin suppresses FoxO3a activity via AMPK 
activation, resulting in suppression of SeP expression. Thus the hypoglycemic effects of metformin may be 





Primers used in cloning 
SEPP1-Promoter-Luc Forward hSeP-promoter-F-BglII ACTAGATCTACAAACCTTTCAGACACTGAGTTG 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-A Forward hSeP-Promoter-Del-F1-BglII ACTAGATCTGGGCTGCCTGTCTTTGATTTCACAT 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mu-B Forward hSeP-Promoter-Del-F2-BglII ACTAGATCTTTGTAGTTCCTGCACCTTGTACAAC 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-C Forward hSeP-Promoter-Del-F3-BglII ACTAGATCTGCATAGGTCTTCCAGGAAGTACGAC 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-D Forward hSeP-Promoter-Del-F4-BglII ACTAGATCTCAAATGTTTTTCCCTGTTATAGTTT 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-E Forward hSeP-promoter-F-BglII ACTAGATCTACAAACCTTTCAGACACTGAGTTG 
 Reverse hSeP-promoter-Del-R1-NocI ACTCCATGGCTGAGCCAGCGAATTATGCTGCTGC 
Mut-DΔ1 Forward hSeP-Promoter-Del-F14-BglII ACTAGATCTGATTCTAGGGTGACTGAAAAGGATA 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-DΔ2 Forward hSeP-Promoter-Del-F15-BglII ACTAGATCTATAACAATCAGCTCAGGGGTTTGCT 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-DΔ3 Forward hSeP-Promoter-Del-F16-BglII ACTAGATCTATAAATATCAGAGTGTGCTGCTGTG 
 Reverse hSeP-promoter-R-NcoI ACTCCATGGACAACCACTTCCAACGGGCCTGCTT 
Mut-DΔ2-ΔFoxo #A Forward del86-95 GACTATACCTGAGGGGTGAGGGACTATAAATATCAGAGTG 
 Reverse del86-95-antisense CACTCTGATATTTATAGTCCCTCACCCCTCAGGTATAGTC 
Mut-DΔ2-ΔFoxo #B Forward hSeP-del-Foxo #3-F GAGGTAAACAACAGGACTAAGAGTGTGCTGCTGTGG 
 Reverse hSeP-del-Foxo #3-R CCACAGCAGCACACTCTTAGTCCTGTTGTTTACCTC 
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